Immediate-Release + Delayed-Release Drug Delivery
This proprietary biphasic formulation technology is designed to combine an immediate-release component that delivers therapeutic drug levels rapidly with a delayed-release component that provides sustained exposure over time. By optimizing the timing and pharmacokinetic profile of drug delivery, the platform has the potential to improve efficacy, extend therapeutic benefit, enhance patient adherence, and differentiate existing pharmaceutical compounds.
Immediate-Release
Rapid onset of therapeutic activity. Active drug becomes bioavailable within minutes, quickly reaching effective plasma concentrations.
Delayed-Release
Sustained therapeutic exposure over time. A second release event extends drug coverage, smoothing the pharmacokinetic profile and supporting once-daily dosing.
Biphasic Drug Delivery Platform — A Dual-Phase Release Architecture for Short Half-Life Pharmaceuticals
A patented immediate-release / delayed-release oral delivery platform applicable across a broad range of pharmaceutical compounds. Biphasic / Combo is presented in the patent as an illustrative example application — the underlying invention is a platform technology.
+
Delayed-Release
PSC / PBC Portfolio
A complementary set of therapeutic-use patents focused on rare hepatobiliary diseases — primary sclerosing cholangitis and primary biliary cholangitis.
Method for Treating Primary Sclerosing Cholangitis
Novel therapeutic method patent directed to the treatment of primary sclerosing cholangitis (PSC), a rare hepatobiliary disease with limited approved therapies.
Use of SGLT2 Inhibitors to Treat Primary Sclerosing Cholangitis
Novel use patent covering the application of SGLT2 inhibitor compounds for the treatment of primary sclerosing cholangitis.
Use of SGLT2 Inhibitors to Treat Primary Biliary Cholangitis
Novel use patent covering SGLT2 inhibitor compounds for the treatment of primary biliary cholangitis (PBC), a progressive autoimmune cholestatic liver disease.